BioMendics Advances First-in-Class Therapy for Epidermolysis Bullosa Simplex with TAMES-02 Trial
核心洞察
BioMendics (搜索) is developing TolaSure, a topical therapy designed to strengthen keratinocyte (搜索) integrity and reduce blister formation at the molecular level for Epidermolysis Bullosa Simplex (搜索) patients.
The company's TAMES-02 trial, launched in August 2025, is a multicenter, randomized, double-blind, placebo-controlled study evaluating TolaSure in patients aged four years and older with moderate to severe EB Simplex (搜索).
TolaSure has received FDA Orphan Drug Designation and Rare Pediatric Disease Voucher status, positioning it as a potential first disease-modifying therapy for a condition affecting an estimated 35,000 patients in the U.S.
BioMendics (搜索) is advancing what could become the first disease-modifying therapy for Epidermolysis Bullosa Simplex (搜索) (EB Simplex (搜索)), a rare genetic skin disorder that affects an estimated 35,000 patients in the United States. The Ohio-based biotechnology company is actively enrolling patients in its pivotal TAMES-02 clinical trial for TolaSure, a first-in-class topical therapy designed to strengthen keratinocyte (搜索) integrity and directly reduce blister formation at the molecular level.
For families living with EB Simplex (搜索), the condition presents daily challenges with fragile blistering skin and constant pain that impacts mobility and daily activities. The disorder, caused by gene mutations that weaken the skin's structural proteins, leaves even the lightest friction capable of causing blistering. Despite decades of research, no FDA-approved treatments exist beyond palliative wound care and infection management.
TAMES-02 Trial Design and Objectives
Launched in August 2025, TAMES-02 is a multicenter, randomized, double-blind, placebo-controlled clinical trial co-led by Northwestern Feinberg School of Medicine (搜索) Department of Dermatology and Stanford University School of Medicine Department of Dermatology. The trial evaluates TolaSure in generalized intermediate to severe EB Simplex (搜索) patients aged four years and older over a 6-month period.
The study design includes a two-month randomized phase where participants receive either TolaSure or placebo gels, followed by a two-month extension where all participants receive TolaSure, and a two-month follow-up period to assess sustained outcomes.
Dr. Joyce Teng, Principal Investigator at Stanford University, noted that "early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex (搜索) community." She emphasized that clinical research in rare skin diseases requires collaboration with companies like BioMendics (搜索) and patient advocacy groups to accelerate progress toward transformative therapies.
Clinical Focus and Endpoints
A major focus of the trial centers on blister surface area changes over treated body regions. The study also assesses plantar blistering on the soles of the feet, identified as one of the most painful and functionally limiting aspects of EB Simplex (搜索). According to the company, the goal is to gain a deeper understanding of meaningful outcomes for the EB Simplex community, representing an important step toward approval of a new therapy.
Dr. Amy Paller, Principal Investigator at Northwestern University, described TAMES-02 as "a vital next step," noting that the collaboration enables rigorous evaluation of the therapy for patients who have had limited options.
Market Opportunity and Regulatory Status
EB Simplex (搜索) accounts for roughly 70% of the 80,000 epidermolysis bullosa cases in the U.S., creating an addressable market of approximately 35,000 patients. Patient surveys indicate that 92% of those affected cite blistering and skin fragility as their top concern, highlighting the inadequacy of current symptom management approaches.
TolaSure has received U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Voucher status, providing pathways for accelerated approval opportunities. BioMendics (搜索) has built a patent portfolio spanning 12 issued patents across major global markets with 15 pending applications, supporting both regulatory progress and commercial scalability.
Company Leadership and Vision
"Our mission at BioMendics (搜索) is to bring science and compassion together for families who have waited far too long for effective treatment," said Dr. Karen McGuire, Founder and CEO of BioMendics. "TolaSure represents an entirely new approach to EB Simplex (搜索) therapy — one that targets the biology of the disease instead of just managing symptoms."
McGuire emphasized that TolaSure's potential impact extends beyond treating blisters to restoring confidence, mobility, and comfort for people who have endured daily pain, describing the company's progress as "an inflection point for BioMendics (搜索) and for families living with EB Simplex (搜索) worldwide."
BioMendics (搜索) operates as part of the REDIzone Innovation Hub at Northeast Ohio Medical University (NEOMED), leveraging academic and regional partnerships to accelerate development from laboratory to clinic. The company is preparing to present its progress at the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco.